일동제약

249420KOSPI의약품 제조업

44.5 / 100

Reference Date: 2026-07-24

Financial Score13.5 / 40

News Sentiment18.0 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Plunged 20.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Il Dong Pharmaceutical is a company engaged in the manufacture and sale of pharmaceuticals, raw materials, and health supplements. Key products include Aronamin, Furumarin, and Laviert, with sales of 614,941 million won in the 9th fiscal year. Products are distributed domestically and internationally through channels such as wholesale, retail, and hospitals, with active R&D investments.

Number of Employees

1,104people

Average Salary

79.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

14.78Industry Average 11.233.0Point

Higher than industry avg (caution)

PBR

1.84Industry Average 0.810.0Point

2.3x industry avg (risky)

ROE

11.89Industry Average 4.017.0Point

3.0x industry avg (excellent)

Debt Ratio

42.82Industry Average 12.430.0Point

3.4x industry avg (risky)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼2.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲86.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.0% (improving, 3yr)

Detailed News Sentiment

22 totalPositive 14Neutral 7Negative 1Average Sentiment Score 72

Neutral
K-멜로디 사업단, 올해 신규 과제 본격 착수
협회 주도 프로젝트 발표로 일동제약 직접적 영향은 제한적.
Neutral
‘주주가치 보호’ 앞세운 중복상장 규제…휴온스·알테오젠 셈법 복...
금융당국의 중복상장 규제 강화가 제약바이오 업계 전반에 영향을 미치나, 일동제약에 대한 직접적인 영향은 제한적이다.
Positive
‘먹는 위고비’ 유럽에도 상륙…K제약사 개발 경쟁 치열해진다
유럽 진출로 인한 글로벌 시장 확대가 일동제약의 경쟁력 강화에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 13,920Won52-week high 44,30052-week low 13,450

1-month return0.0Point

1m -20.82% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0